According to research analysts, the Global Vacation Rental Market will hit $169.7 billion by 2019. The main areas where global vacation rental adoption is highest are North America and Europe. This is because of the concept of a timeshares. Also, technological innovation is leading to an increase in supply while a higher interest in vacation rentals is increasing demand is leading to market growth. Travelers are now becoming more attracted to business intelligence software in order to find the best decisions for their vacations. Tools such as this help smaller companies find their way into the market instead of allowing the industry to become monopolistic.
At the moment, Strategic Global Investments, Inc. (OTCMKTS:STBV) has a ten-acre property in Los Cabos, Baja that is currently a substantial asset base and will be a great source of future income. Strategic Global Investments, Inc. has finally acquired all of the necessary building permits, environmental and government approvals that are needed to construct the units that they have planned. The company owns a real estate development subsidiary, which focused on making Eco-friendly, luxury real estate in vacation areas with high demand. This subsidiary is trying to acquire and develop land to build small luxury resort homes, or Small Luxury Villas (SLV for short) on a timeshare system.
The plans to complete the first SLV was finalized in October. In a corporate update, Strategic Global Investments, Inc. specified that it would be putting great focus on finish the Time Share property owned in Los Cabos, Baja, Mexico. Reports indicate that the economic environment has become a major benefit for the company’s plans to finish its ongoing business plan and finish their SLV. At the moment, the 5000 square foot showcase SLV is 65% complete. The other twenty-nine villas on the debt free property will be between 2300 to 2500 square feet and will be constructed according to market demands.
CEO of Strategic Global Investments, Inc. (OTCMKTS:STBV), Andrew Fellner, stated, “We initially invested in the project prior to the 2008 market crash. We’ve since seen a massive recovery in the time share market, which has prompted us to continue construction of our first Villa to meet current market demand. It’s a very exciting time for the Company and to see our new business plan coming to fruition further validates our vision.” As mentioned, the demand for this products is increasing and proving to be great for STBV. Over the last ninety days, STBV has seen lows of $0.0056 and a difference of 1507% with highs of $0.09.
Important Disclaimer Information
The writer of this opinion is affiliated with a company (Midam) which is publicly disseminating information about (STBV) including on the Website and other media including Facebook and Twitter. Midam owns 1,666,667 shares of Strategic Global, Inc. which may be sold at any time in the open market which were earned for consulting services. We plan to sell the shares of (STBV) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (STBV) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. For full disclaimer please view the full disclaimer here.
Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)
Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.
REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.
REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.
CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.
Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).
Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.
ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast
ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.
ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.
CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.
MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.
The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.
Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)
Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.
CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.